Oncternal Therapeutics, Inc. revenue for the last year amounted to 785.00 k USD, the most of which — 785.00 k USD — came from its highest performing source at the moment, Novel Oncology Therapies, the year earlier bringing 1.49 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought Oncternal Therapeutics, Inc. 785.00 k USD, and the year before that — 1.49 M USD.